Oncopeptides AB Cash Flow Conversion Efficiency
Oncopeptides AB cash flow conversion efficiency. Based on the latest financial reports, Oncopeptides AB (ONCO) has a cash flow conversion efficiency ratio of 3.676x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-216.49 Million ≈ $-23.30 Million USD) by net assets (Skr-58.89 Million ≈ $-6.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncopeptides AB (2014–2025)
Cash flow conversion efficiency of Oncopeptides AB from 2014 to 2025. This chart illustrates how Oncopeptides AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ONCO share price today for real-time trading data and today's change.
Oncopeptides AB Cash Flow Conversion Ratio Explained
Oncopeptides AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncopeptides AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncopeptides AB ranked by their cash flow conversion efficiency. Also see Oncopeptides AB market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xchanging Solutions Limited
NSE:XCHANGING
|
0.045x |
|
Satia Industries Limited
NSE:SATIA
|
0.082x |
|
Trinity Precision Technology Co Ltd
TWO:4534
|
-0.019x |
|
Great Elm Capital Corp
NASDAQ:GECC
|
0.119x |
|
MediciNova Inc
NASDAQ:MNOV
|
-0.039x |
|
ABITARE IN S.P.A.
F:1BN
|
-0.033x |
|
Simply Better Brands Corp
V:SBBC
|
-0.789x |
|
Hyundai Everdigm Corp
KQ:041440
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Oncopeptides AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Oncopeptides AB from 2014 to 2025. Review cash generation quality of Oncopeptides AB to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-58.89 Million ≈ $-6.34 Million |
Skr-222.88 Million ≈ $-23.99 Million |
3.785x | +178.85% |
| 2024-12-31 | Skr54.28 Million ≈ $5.84 Million |
Skr-260.57 Million ≈ $-28.04 Million |
-4.800x | +2.49% |
| 2023-12-31 | Skr56.78 Million ≈ $6.11 Million |
Skr-279.49 Million ≈ $-30.08 Million |
-4.922x | -244.49% |
| 2022-12-31 | Skr294.29 Million ≈ $31.67 Million |
Skr-420.51 Million ≈ $-45.25 Million |
-1.429x | +80.13% |
| 2021-12-31 | Skr210.87 Million ≈ $22.69 Million |
Skr-1.52 Billion ≈ $-163.19 Million |
-7.191x | -219.98% |
| 2020-12-31 | Skr576.90 Million ≈ $62.08 Million |
Skr-1.30 Billion ≈ $-139.53 Million |
-2.247x | -159.38% |
| 2019-12-31 | Skr797.01 Million ≈ $85.77 Million |
Skr-690.57 Million ≈ $-74.32 Million |
-0.866x | +18.00% |
| 2018-12-31 | Skr315.83 Million ≈ $33.99 Million |
Skr-333.73 Million ≈ $-35.91 Million |
-1.057x | -62.69% |
| 2017-12-31 | Skr418.00 Million ≈ $44.98 Million |
Skr-271.50 Million ≈ $-29.22 Million |
-0.650x | +83.59% |
| 2016-12-31 | Skr26.34 Million ≈ $2.83 Million |
Skr-104.26 Million ≈ $-11.22 Million |
-3.959x | -119.49% |
| 2015-12-31 | Skr-2.60 Million ≈ $-279.80K |
Skr-52.81 Million ≈ $-5.68 Million |
20.311x | +591.36% |
| 2014-12-31 | Skr7.61 Million ≈ $818.48K |
Skr-31.44 Million ≈ $-3.38 Million |
-4.134x | -- |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more